Navigation Links
Palatin Technologies' Listing Compliance Plan Accepted by NYSE Alternext US
Date:3/5/2009

CRANBURY, N.J., March 5 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Alternext US: PTN) reported that its exchange listing compliance plan submitted on January 23, 2009 has been accepted by the NYSE Alternext US LLC (the "Exchange," formerly known as the American Stock Exchange).

As reported on December 30, 2008, Palatin received notice from the Exchange that it was not in compliance with certain continued listing requirements under Sections 1003(a)(ii) and (iii) of the Exchange's Company Guide related to historical operating losses and shareholders' equity levels. This notice is described in more detail in Palatin's report on Form 8-K which was filed on December 30, 2008.

On February 27, 2009, the Exchange notified Palatin that it had accepted Palatin's plan for regaining compliance with the continued listing requirements of Sections 1003(a)(ii) and (iii), and that Palatin's listing on the Exchange was being continued pursuant to an extension.

Palatin may be able to continue its listing on the Exchange during the plan period through June 23, 2010, subject to periodic review by the Exchange to determine if Palatin is making progress consistent with the plan. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by June 23, 2010 could result in Palatin's shares being delisted from the Exchange. If Palatin's common stock was ultimately delisted from the Exchange, it would be expected to trade on the over-the-counter market, such as the OTC Bulletin Board securities market, a regulated quotation service that provides quotes, sale prices and volume information in over-the-counter equity securities.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics.
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
11. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...France, April 23 , - Strong 10.3% Growth in F...the world leader in ophthalmic optics, today,annou...the three months ended,March 31, 2009, representin...f 2008. Excluding the currency effect, growth was ...and early in the year, revenue was down just 1%,li...
...l 22 Hovione held today the opening,ceremony of i...ing site in,Cork. Hovione contracted with Pfizer l...anufacturing Lipitor(R) since 1997. The handover o...ction closed on the 8th; going forward,Hovione wil...e for Pfizer but,will mostly make use of the avail...
...inducted into National Academy of Sciences for gro... WASHINGTON, April 22 Sir Philip Cohen of Scotlan...he U.S. National Academy of Sciences (NAS) during ...8:00 p.m. at the NAS building for his excellence i...of only four Scottish scientists ever inducted int...
Other Biology Technology:Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Hovione Opens its New API Plant in Cork 2Hovione Opens its New API Plant in Cork 3United States Recognizes Leading Scottish Scientist for Disease Research 2
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
(Date:12/3/2009)PHILADELPHIA Now in its 32nd year, the CTRC-AACR San Antonio Breast Cancer Symposium continues to attract the best in breast cancer science and world leaders from industry and academia with the goal
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
Breaking Biology News(10 mins):Papillomavirus silences innate immune response 2CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 1HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 1CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 2CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 4Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 1Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 2Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 3Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 4
...ester scientists are to investigate the biological... after Alzheimer,s, thanks to a prestigious 1.9 mi...earch Council. , Frontotemporal lobar degeneratio...rontal and temporal lobes of the brain and are cha...rather than the memory loss associated with Alzhei...
...utions to Identify Individuals for Access to ...ions, WALL, N.J., Sept. 22 BIO-key International...er-based biometric,identification and wireless pub...etwork, is showcasing its fingerprint biometric so... being held at the Moscone Center in San,Francisco...
...A glitch in the ability to move iron around in cel...idosis (ML4) and the suite of symptoms---mental re...ies---that accompany it, new research at the Unive... may be involved in aging and neurodegenerative di...ead author Haoxing Xu, an assistant professor of m...
Other Biology News:£2 million study to reveal workings of dementia genes 2BIO-key(R) International To Exhibit at Oracle OpenWorld 2BIO-key(R) International To Exhibit at Oracle OpenWorld 3BIO-key(R) International To Exhibit at Oracle OpenWorld 4Iron-moving malfunction may underlie neurodegenerative diseases, aging 2Iron-moving malfunction may underlie neurodegenerative diseases, aging 3
... containing a clone of the human Topoisomerase II ... topological state of nucleic acids by passing an ...enerates a separate DNA helix (1,2) . As a result ...enzyme can relax negatively or positively supercoi...
...I catalyzes the template-directed polymerization o...DNA Polymerase I possesses a 3?5 exonuclease activ...rror rate during DNA replication, and also contain...zyme to replace nucleotides in the growing strand ...
...e Klenow Fragment is a genetically engineered Klen...vity has been removed, leaving only the 5 to 3 pol...ctivity makes Exo- Klenow Fragment the enzyme of c...s by the random primed method, and for DNA sequenc...
T7 RNA Polymerase from Invitrogen
Biology Products: